Systemic mastocytosis - A systematic review

Danish Medical Journal

Volumn 59, Issue 3, 2012, Pages

  Andersen, Christen Lykkegaard ^a,e   Kristensen, Thomas Kielsgaard ^b   Severinsen, Marianne Tang ^c   Møller, Michael Boe ^b   Vestergaard, Hanne ^b   Bergmann, Olav J ^d   Hasselbalch, Hans Carl ^a   Bjerrum, Ole Weis ^e  

^a ROSKILDE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d University of Esbjerg   (Denmark)

^e International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLADRIBINE; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE; STEM CELL FACTOR; TRYPTASE; VITAMIN D;

CELL PROLIFERATION; CYTOLOGY; DEGRANULATION; DIET SUPPLEMENTATION; EXOCYTOSIS; GENE EXPRESSION; HUMAN; MAST CELL; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; SKIN DEFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA; PATHOLOGY; PROGNOSIS;

GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; PROGNOSIS;

EID: 84873196499     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Erlich P. Beitrage zur theorie und praxis der histologischen färbung. Leipzig, Germany: University of Leipzig, 1878.
2. Nettleship E, Tay W. Rare forms of urticaria. Br Med J 1869;2:323-30.
3. Arinobu Y, Iwasaki H, Akashi K. Origin of basophils and mast cells. Allergol Int 2009;58:21-8.
4. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008;9:1215-23.
5. Hallgren J, Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J 2006;273:1871-95.
6. Pejler G, Ronnberg E, Waern I et al. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 2010;115:4981-90.
7. Metcalfe DD. Mast cells and mastocytosis. Blood 2008;112:946-56.
8. Gurish MF, Austen KF. The diverse roles of mast cells. J Exp Med 2001;194: F1-F5.
9. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77:1033-79.
10. Chen CC, Grimbaldeston MA, Tsai M et al. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A. 2005;102:11408-13.
11. Iwasaki H, Mizuno S, Arinobu Y et al. The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev 2006;20:3010-21.
12. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135-42.
13. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 1989;7:59-76.
14. Lutzelschwab C, Pejler G, Aveskogh M et al. Secretory granule proteases in rat mast cells. Cloning of 10 different serine proteases and a carboxypeptidase A from various rat mast cell populations. J Exp Med 1997;185:13-29.
15. Horny H, Akin C, Metcalfe D. Mastocytosis. In: Swerdlow SH et al, eds. WHO classification of tumours of haematopoietic and lymphoid origin. Lyon: IARC, 2008:54-63.
16. Galli SJ, Kalesnikoff J, Grimbaldeston MA et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749-86.
17. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004;114:13-9; quiz 20.
18. Kristensen T, Vestergaard H, Moller MB. Improved Detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011;13:180-8.
19. Hagglund H, Gulen T, Saaf M et al. [Mastocytosis-a disease with many faces. Investigation and treatment should be performed in consultation with Karolinska University Hospital]. Läkartidningen 2008;105:3341-4, 3346-7.
20. Kirshenbaum AS, Kettelhut BV, Metcalfe DD et al. Mastocytosis in infants and children: recognition of patterns of skin disease. Allergy Proc 1989;10:17-21.
21. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:519-28.
22. Lim KH, Tefferi A, Lasho TL et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-36.
23. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000;14:537-55, vi.
24. Austen KF. Systemic mastocytosis. N Engl J Med 1992;326:639-40.
25. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002;127:147-52.
26. Horny H, Sotlar K, Valent P. Mastocytosis. In: Hematopathology. Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber DA, eds. Philadelphia: Elsevier Saunders, 2011:757-76.
27. Escribano L, Diaz-Agustin B, Bellas C et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001;25:563-70.
28. Orfao A, Garcia-Montero AC, Sanchez L et al. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
29. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008:54-63.
30. Andersen CL, Vestergaard H, Norgaard P et al. Eosinophilia-pathogenesis, classification and therapy. Ugeskr Læger 2009;171:3256-62.
31. Escribano L, Alvarez-Twose I, Sanchez-Munoz L et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-21.
32. Castells M, Akin C et al. Treatment and prognosis of systemic mastocytosis. UpToDate 191, 2011.
33. Wilson TM, Metcalfe DD, Robyn J. Treatment of systemic mastocytosis. Immunol Allergy Clin North Am 2006;26:549-73.
34. Akin C. Anaphylaxis and mast cell disease: What is the risk? Curr Allergy Asthma Rep 2010;10:34-8.
35. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010;116:5812-7.
36. Lim KH, Pardanani A, Butterfield JH et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790-4.
37. Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011;86:362-71.
38. Bjerrum OW. Interferon-alpha treatment in systemic mastocytosis. Curr Drug Targets 2011;12:433-6.
39. Quintas-Cardama A, Aribi A, Cortes J et al. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429-39.
40. Valent P, Akin C, Escribano L et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53.